Tanios Bekaii-Saab, MD, talks with Kristen Ciombor, MD, MSCI, and John Strickler, MD, about targeted therapy resistance, rechallenge, and acquired resistance mutations in colorectal cancer.
This week, CancerNetwork® looks at the final part of its 3-part series focused on colorectal cancer. Tanios Bekaii-Saab, MD, medical director of the Cancer Clinical Research Office and vice chair and section chief for Medical Oncology at the Mayo Clinic in Phoenix, Arizona, concludes his conversation with Kristen Ciombor, MD, MSCI, associate professor of medicine at Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, and John Strickler, MD, associate professor of medicine and co-leader of the Molecular Tumor Board at Duke University School of Medicine in Durham, North Carolina.
This conversation focuses on resistance to targeted therapies in metastatic colorectal cancer and how this unmet need in the field has far-reaching implications. The experts also discuss common therapy resistance, rechallenge after prior progression, and acquired mutations arising after targeted therapy.
Thanks for tuning in to this series on colorectal cancer from CancerNetwork®. Visit cancernetwork.com to catch up on any episodes you missed and to read more about these topics published in the journal ONCOLOGY®.
Take a listen to the first and second episodes of this colorectal cancer podcast series:
Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.